Search
Research
Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescentsThis trial evaluated the lot consistency, early immune responses and safety of the vaccine against serogroup B Neisseria meningitidis (4CMenB) - in 11 to 17...
Research
Multidrug-resistant tuberculosis in Western Australia, 1998-2012Our objective was to describe the epidemiology, clinical features, health care resource use, treatment and outcomes of multidrug-resistant tuberculosis...
Research
CD46 measles virus receptor polymorphisms influence receptor protein expressionDespite the availability of measles vaccines, infants continue to die from measles. Measles vaccine responses vary between individuals, and poor...
Research
Toll-like receptor 7 and 8 polymorphisms: Associations with functional effects and cellular and antibody responses to measles virus and vaccineThe functionality and effects of TLR7 and TLR8 polymorphisms on cellular and antibody responses was investigated after the first measles vaccine dose.
Research
Trivalent influenza vaccine and febrile adverse events in australia, 2010: Clinical features and potential mechanismsIncreased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010.
Research
Response after one dose of monovalent influenza A (H1n1) 2009 vaccine in infants and children - preliminary reportTo assess the immunogenicity and safety of a 2009 influenza A(H1N1) vaccine in children.
News & Events
Perth mums play instrumental part in world-first vaccineNew mothers in Perth are teaming up with researchers at The Kids Research Institute Australia in a global bid to develop the first vaccine to prevent Respiratory Syncytial Virus (RSV) disease.
People
Professor Christopher BlythCentre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Honorary and NHMRC Career Development Fellow, Paediatric Infectious Diseases Physician and Clinical Microbiologist
Research
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocolCoronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
Research
The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.